QV Investors Inc. Makes New $7.77 Million Investment in Hims & Hers Health, Inc. $HIMS

QV Investors Inc. bought a new position in Hims & Hers Health, Inc. (NYSE:HIMS) in the 2nd quarter, Holdings Channel.com reports. The firm bought 224,130 shares of the company’s stock, valued at approximately $7,771,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Versant Capital Management Inc increased its stake in shares of Hims & Hers Health by 801.2% during the second quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock worth $26,000 after acquiring an additional 665 shares during the period. MassMutual Private Wealth & Trust FSB lifted its position in Hims & Hers Health by 70.0% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock valued at $27,000 after purchasing an additional 319 shares during the period. Binnacle Investments Inc acquired a new stake in Hims & Hers Health in the third quarter valued at about $28,000. Geneos Wealth Management Inc. purchased a new stake in Hims & Hers Health in the 1st quarter valued at approximately $30,000. Finally, Greenline Wealth Management LLC purchased a new stake in Hims & Hers Health in the 4th quarter valued at approximately $36,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Zacks Research raised Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Morgan Stanley lifted their price target on Hims & Hers Health from $21.00 to $28.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 11th. Citigroup dropped their price objective on Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating on the stock in a report on Tuesday, August 11th. BTIG Research reiterated a “neutral” rating on shares of Hims & Hers Health in a research report on Tuesday, May 12th. Finally, Canaccord Genuity Group raised their target price on Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Four equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $32.50.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers continues to attract attention for its expansion in telehealth and weight-loss treatments. Recent analysis highlights the company’s broader growth opportunity, while second-quarter revenue rose 38.2% year over year to $753.2 million, exceeding expectations. Hims & Hers Is Growing Into Something Much Bigger
• Neutral Sentiment: Chief Executive Officer Andrew Dudum pushed back against the Federal Trade Commission’s position, arguing that the agency does not fully understand Hims & Hers’ business. The dispute may shape investor views of the company’s ability to defend its practices and continue operating its weight-loss platform. Hims & Hers CEO Says the FTC Doesn’t Understand His Own Company
• Negative Sentiment: Visa reportedly placed Hims & Hers in its Acquirer Monitoring Program after a rise in credit-card billing disputes. Potential penalties or increased payment-processing scrutiny could raise costs and pressure the company’s already declining gross margin. Hims & Hers Weight-Loss Plans Results Penalties Over Visa Credit Card Disputes
• Negative Sentiment: Separate reports describe FTC scrutiny involving health-data sharing and tracking tools. Regulatory action could increase compliance costs, limit marketing practices or damage customer trust. FTC Targets Hims & Hers Over Health Data Sharing
• Negative Sentiment: Kaplan Fox and Pomerantz announced investigations into potential violations of federal securities laws. These announcements do not establish wrongdoing, but they add legal uncertainty, potential costs and headline risk for shareholders. Kaplan Fox Investigation Pomerantz Investor Investigation
• Negative Sentiment: The company’s latest quarterly results showed an adjusted earnings shortfall despite the revenue beat, reinforcing concerns about profitability and valuation as regulatory and operating pressures increase. Unpacking Q2 Earnings

Insider Transactions at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 55,383 shares of the firm’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $35.09, for a total value of $1,943,389.47. Following the completion of the transaction, the chief financial officer owned 228,938 shares in the company, valued at $8,033,434.42. This trade represents a 19.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Deborah M. Autor sold 16,773 shares of Hims & Hers Health stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $27.85, for a total transaction of $467,128.05. Following the transaction, the insider owned 48,961 shares of the company’s stock, valued at approximately $1,363,563.85. The trade was a 25.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 186,769 shares of company stock worth $6,035,648 over the last ninety days. 11.76% of the stock is currently owned by corporate insiders.

Hims & Hers Health Trading Up 0.1%

Shares of HIMS opened at $28.88 on Monday. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21. The firm’s 50-day moving average is $32.14 and its two-hundred day moving average is $26.40. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $65.30. The firm has a market capitalization of $6.74 billion, a P/E ratio of -45.84 and a beta of 2.40.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). The company had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. Hims & Hers Health’s revenue was up 38.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.17 earnings per share.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.